<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362105">
  <stage>Registered</stage>
  <submitdate>16/02/2012</submitdate>
  <approvaldate>20/02/2012</approvaldate>
  <actrnumber>ACTRN12612000209897</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of Chinese herbal medicine (RCM-102) for treatment of seasonal allergic rhinitis (hayfever)</studytitle>
    <scientifictitle>Pharmacological actions and clinical evaluation of a Chinese Herbal formula in the treatment of seasonal allergic rhinitis: A double blind, randomized, placebo-controlled trial.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Application (2003/70) was filed with the Clinical Trials Branch under its Clinical Trial Notification (CTN) Scheme, Therapeutic Goods Administration (TGA), Department for Health and Ageing, Canberra, Australia</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>seasonal allergic rhinitis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Astragalus membranaceus (Fisch.) Bge
Bupleurum chinense D.C 
Glycyrrhiza uralensis (Fisch.)
Magnolia liliflora (Desr.)
Mentha haplocalyx Briq.
Schizonepeta Tenuifolia Briq.
Saposhnikovia divaricata (Turcz.)
Scutellaria baicalensis Georgi. 


two capsules each time, three times daily (with four hours interval) for a period of eight weeks durong the pollen season (semtember-December). Each capsule contained 500 mg of a mixture of granules of either herbal medicine (Koda Internationals Pty Ltd, Lane Cove, N.S W. Australia) or placebo ingredient (rice starch from Sigma Pharmaceuticals Pty Ltd (Melbourne, Victoria, Australia).</interventions>
    <comparator>Rice starch capsules</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>nasal symptoms  (sneezing; rhinorrhea; itchy nose; obstruction) and non-nasal symptoms (palate, and/or throat; itchy, watery, red eye) on a 5-point scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe,  using a symptoms severity five-point scale, VAS,</outcome>
      <timepoint>Day 1, 14, 28, 42,56,70</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>General Quality of Life (SF36)</outcome>
      <timepoint>Day 1, 14, 28, 42,56,70</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).</outcome>
      <timepoint>Day 14, 28, 42,56,70</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Liver and kidney function test</outcome>
      <timepoint>Day 1 and Day 70</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(a) age between 18 to 65 years with two or more symptoms  for at least two years with a total nasal symptom score (TNSS) of at least six; 
(b) a positive pollen skin prick test (SPT).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(a) initiated immunotherapy since last SAR season; 
(b) HIV positive; 
(c) other active respiratory disease within 30 days of study; (d) receiving oral corticosteroid treatment; 
(e) pregnancy or lactation;
 (f) nasal polyposis; and 
(g) unable to read or understand English.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomisation will be achieved using clinical computer software package STUDY MANAGER which also generates the treatment code and a patient code. This computer program will be protected from unauthorised entry by a password.
Blinding will be achieved by using pre-packing of placebo and real NSARF capsules with identical appearance and smell.   The codes and labelling will be recorded  by a password protected computer program.</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/09/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>104</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Charlie Xua</primarysponsorname>
    <primarysponsoraddress>RMIT University
Bundoora West campus
PO Box70
Bundoora VIC 3083</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>RMIT University</fundingname>
      <fundingaddress>RMIT University
Bundoora West campus
PO Box70
Bundoora VIC 3083</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Subjects were required to take two capsules each time, three times daily (with four hours interval) for a period of eight weeks. Each capsule contained 500 mg of a mixture of granules of either herbal medicine (Koda Internationals Pty Ltd, Lane Cove, N.S W. Australia) or placebo ingredient (rice starch from Sigma Pharmaceuticals Pty Ltd (Melbourne, Victoria, Australia). The capsules were prepared by a TGA approved Good Manufacturing Practice (GMP) certified manufacturer (GMP Pharmaceuticals Pty Ltd Girraween, N.S.W. Australia). The two types of capsules were identical in weight and appearance.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>RMIT HREC</ethicname>
      <ethicaddress>RMIT University
Bundoora West campus
PO Box70
Bundoora VIC 3083</ethicaddress>
      <ethicapprovaldate>30/10/2002</ethicapprovaldate>
      <hrec>HREC18/02</hrec>
      <ethicsubmitdate>2/10/2002</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr George Lenon</name>
      <address>RMIT University
Bundoora west campus
Plenty Rd
Bundoora
Victoria 3083

POBox 70
Bundoora 3083</address>
      <phone>+61399256587</phone>
      <fax>+61399257178</fax>
      <email>george.lenon@rmit.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>George Lenon</name>
      <address>RMIT University
Bundoora west campus
Plenty Rd
Bundoora
Victoria 3083

POBox 70
Bundoora 3083</address>
      <phone>+61399256587</phone>
      <fax>+61399257178</fax>
      <email>george.lenon@rmit.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr George Lenon</name>
      <address>RMIT University
Bundoora west campus
Plenty Rd
Bundoora
Victoria 3083

POBox 70
Bundoora 3083</address>
      <phone>+61399256587</phone>
      <fax>+61399257178</fax>
      <email>george.lenon@rmit.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>